Between the Lines: Expanding Treatment Options in Retina Diseases with Biosimilars

home / video-series / between-the-lines-expanding-treatment-options-in-retina-diseases-with-biosimilars

Expert retina specialists discuss the efficacy and safety data of the ranibizumab biosimilar, SB11, and explore the practical implications of biosimilars in the broader real-world context.

New content coming soon.
© 2024 MJH Life Sciences

All rights reserved.